Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.27 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 72 |
| Open | 71.84 |
| 1-Year Change | 16.97% |
| Day's Range | 71.84 - 73.71 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 73.42 | 1.31 | 1.82% | 72.11 | 73.88 | 71.44 |
| Jan 17, 2025 | 71.86 | -0.16 | -0.22% | 72.02 | 72.76 | 71.60 |
| Jan 16, 2025 | 72.19 | 0.34 | 0.47% | 71.85 | 72.91 | 71.65 |
| Jan 15, 2025 | 72.14 | -0.20 | -0.28% | 72.34 | 73.66 | 72.05 |
| Jan 14, 2025 | 71.86 | 0.50 | 0.70% | 71.36 | 72.83 | 70.95 |
| Jan 13, 2025 | 72.11 | 1.65 | 2.34% | 70.46 | 72.83 | 69.41 |
| Jan 10, 2025 | 70.45 | -1.60 | -2.22% | 72.05 | 72.05 | 69.39 |
| Jan 8, 2025 | 73.02 | 0.09 | 0.12% | 72.93 | 73.91 | 72.66 |
| Jan 7, 2025 | 73.16 | 0.19 | 0.26% | 72.97 | 74.90 | 72.32 |
| Jan 6, 2025 | 71.61 | 2.32 | 3.35% | 69.29 | 72.70 | 68.98 |
| Jan 3, 2025 | 69.48 | 0.86 | 1.25% | 68.62 | 70.31 | 68.62 |
| Jan 2, 2025 | 69.21 | -0.11 | -0.16% | 69.32 | 69.90 | 68.75 |
| Dec 31, 2024 | 69.02 | 1.13 | 1.66% | 67.89 | 69.12 | 67.89 |
| Dec 30, 2024 | 68.18 | 0.07 | 0.10% | 68.11 | 68.67 | 67.64 |
| Dec 27, 2024 | 69.15 | 0.96 | 1.41% | 68.19 | 69.79 | 67.73 |
| Dec 26, 2024 | 69.40 | 0.21 | 0.30% | 69.19 | 69.99 | 69.19 |
| Dec 24, 2024 | 69.81 | 0.86 | 1.25% | 68.95 | 70.02 | 68.70 |
| Dec 23, 2024 | 69.80 | 1.75 | 2.57% | 68.05 | 70.13 | 67.80 |
| Dec 20, 2024 | 68.78 | 2.76 | 4.18% | 66.02 | 68.96 | 66.02 |
| Dec 19, 2024 | 66.83 | -1.46 | -2.14% | 68.29 | 68.31 | 66.23 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com